Achievements

75 million vials of Artesun® delivered to treat children with severe malaria

 

17 drug candidates brought forward from discovery research since 2010

USD 1 = USD 3.5 of investment impact thanks to direct and in-kind support from partners

Pyramax® Granules received positive scientific opinion from the European Medicines Agency

MMV wins Open Data Innovation Award for work on the Malaria Box
Dr David Reddy, CEO, MMV and Dr Bernard Pécoul, CEO, DNDi

2 ACTs developed by DNDi and partners transitioned to MMV

2 dossiers for rectal artesunate suppositories submitted for WHO prequalification

400 compounds active against neglected diseases available for free to boost drug research

3 million children across the Sahel region benefit from Seasonal Malaria Chemoprevention

8 medicines in clinical development prioritizing eradication and treatment for vulnerable populations including children and pregnant women

300 million treatments of Coartem® Dispersible delivered to over 50 countries

More than 200,000 doses of Eurartesim® distributed in two ground-breaking mass drug administration pilots

18,000 health-care workers trained to administer injectable artesunate for severe malaria

Key landmarks for MMV-supported medicines

Key Achievements over MMV's first 15 years